Rubrik: Pharma-Markt
(Treffer aus pharmind, Nr. 01, Seite 44 (2015))
Müller M | 1The views expressed in this article are the views and opinions of the authors b">Wenninger1The views expressed in this article are the views and opinions of the authors b
Big Pharma at the Crossroads / Recent strategic moves of globally acting pharmaceutical companies · Müller M, Wenninger
1The views expressed in this article are the views and opinions of the authors b · Cepton GmbH, München, Germany
On average, pharma and biotech stocks have shown good performance in 2013, however, most of Big Pharma´s stock price development in 2013 lagged behind the S&P 500 and Dax average. The impact of payors and regulatory bodies continues to grow, influencing not only market access activities, but R&D decisions and business models. Diversification has seen first limits and big players like Abbott, Pfizer and BMS have started to re-focus. Biosimilars and over-the-counter (OTC) drugs have re-entered the spotlight. Regional focus is partly moving on from China to “second-tier” emerging markets like South-East Asia, Iran, Pakistan and Africa. A decrease in ...